Form 4: Sight Sciences Director Catherine Mazzacco Receives Significant RSU Grant

Sight Sciences, Inc. Director Catherine Mazzacco was granted 30,952 Restricted Stock Units (RSUs) valued at approximately $130,000, aligning her interests with shareholders.

Summary

• Catherine Mazzacco, a Director at Sight Sciences, Inc. (SGHT), reported the acquisition of 30,952 Restricted Stock Units (RSUs) on June 5, 2025.
• The grant was made under the Issuer's Non-Employee Director Compensation Program.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The total value of the RSUs granted is approximately $130,000, based on the closing price on the grant date.
• These RSUs will vest on the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on Ms. Mazzacco's continued service as a director.
• Following this transaction, Ms. Mazzacco beneficially owns a total of 78,507 securities, which includes 37,492 shares of Common Stock, the newly granted 30,952 RSUs, and 10,063 RSUs granted on June 8, 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Form 4 is primarily a disclosure, the grant of RSUs to a director indicates continued commitment and alignment of interests, which is generally viewed favorably by investors as it incentivizes long-term performance.

Positives

• The grant of Restricted Stock Units to Director Catherine Mazzacco aligns her interests more closely with those of the company's shareholders.
• The compensation program for non-employee directors helps attract and retain experienced board members.

Risks

• The vesting of the RSUs is subject to the reporting person's continued service as a director, meaning the shares are not immediately owned and could be forfeited if service ceases before vesting.

Future Outlook

The RSUs are scheduled to vest on the earlier of June 5, 2026, and the date of the Issuer's 2026 annual meeting of stockholders, subject to continued service.

Industry Context

This filing represents a routine compensation event for a non-employee director, common across publicly traded companies to incentivize board members and align their interests with long-term shareholder value. It does not provide specific insights into broader industry trends or competitive positioning beyond standard corporate governance practices.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of non-employee director compensation is a standard practice across various industries, including the medical technology sector where Sight Sciences operates.
• The value of the grant (approximately $130,000) falls within typical ranges for annual equity compensation for non-executive directors at companies of similar market capitalization, though specific benchmarks would require detailed peer group analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with the company's performance, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact mentioned, but a stable and incentivized board can contribute to overall company stability.

Next Steps

• The granted RSUs are subject to vesting on the earlier of June 5, 2026, and the date of the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Sight Sciences, SGHT, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Corporate Governance